ATMA Clinical Trials | Evaluating safety and efficacy

Evaluating safety and efficacy with psilocybin clinical trials

ATMA is a forward-thinking psychedelic training and healthcare company, who is actively pursuing research initiatives centered on the therapeutic applications of psilocybin and MDMA for the treatment of various mental health disorders, including PTSD, depression, and anxiety. Motivated by the promising successes documented in published studies, ATMA is committed to advancing the understanding of these substances and their potential to offer transformative relief for individuals facing mental health challenges. The company’s research activities are anchored in the wealth of positive outcomes observed in previous studies, and its mission is to contribute to the growing body of evidence supporting the efficacy of psilocybin- and MDMA-assisted therapy in mental healthcare. ATMA aims to position itself at the forefront of innovative treatment options, fostering a new era of mental health interventions inspired by the success stories emerging from the medical community.

Psilocybin Clinical Trial Phases

Phase I

A Phase I Study with the intent to assess the safety of psilocybin when administered to healthy participants. This clinical trial for psilocybin-assisted therapy evaluated the safety and tolerability of psilocybin in the healthcare practitioners.

Stay tuned for updates regarding future clinical trials sponsored by ATMA

All clinical trial protocols must be formally submitted first to Health Canada and then to a Research Ethics Board for review and approval. While we eagerly await the approvals from both regulatory bodies, it is imperative to emphasize that information specific to each trial we are working on cannot be disclosed until the necessary approvals have been secured.

Start your journey today

Begin your training with us today and take your practice to the next level, helping to shape the future of mental health care.